Lower Breast Cancer Mortality Seen With Estrogen Use

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

SAN FRANCISCO--Use of estrogen supplements may lower breast cancer mortality, an American Cancer Society study has shown. The study, which was discussed at the ACS's science writers meeting, followed 400,000 women who provided data about their cancer risk factors. After 9 years, breast cancer mortality was 16% lower in those women who used estrogen, suggesting that their tumors were less aggressive.

SAN FRANCISCO--Use of estrogen supplements may lower breast cancermortality, an American Cancer Society study has shown. The study,which was discussed at the ACS's science writers meeting, followed400,000 women who provided data about their cancer risk factors.After 9 years, breast cancer mortality was 16% lower in thosewomen who used estrogen, suggesting that their tumors were lessaggressive.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.